Erythropoietin: from erythropoiesis to cardioprotection
Many of the drugs that has shown promise in the treatment of hematologic malignancies and solid tumors, associated with a high potential cardiotoxic. Within this group stand anthracyclines, identified as the type of chemotherapy most likely to cause heart damage, short or long term. With the improve...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Centro Provincial de Información de Ciencias Médicas. Cienfuegos
2010-08-01
|
| Series: | Medisur |
| Subjects: | |
| Online Access: | http://medisur.sld.cu/index.php/medisur/article/view/1159 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832577258711154688 |
|---|---|
| author | Liermis Michael Dita Salabert Ivis Mendoza Hernández Rafael Alejandro Gómez Baute Elena García López Lázaro E. de la Cruz Avilés Aramis Núñez Quintana |
| author_facet | Liermis Michael Dita Salabert Ivis Mendoza Hernández Rafael Alejandro Gómez Baute Elena García López Lázaro E. de la Cruz Avilés Aramis Núñez Quintana |
| author_sort | Liermis Michael Dita Salabert |
| collection | DOAJ |
| description | Many of the drugs that has shown promise in the treatment of hematologic malignancies and solid tumors, associated with a high potential cardiotoxic. Within this group stand anthracyclines, identified as the type of chemotherapy most likely to cause heart damage, short or long term. With the improvement achieved in the survival of patients with these diseases, this adverse event has become a major concern for the scientific community. Although many agents have been evaluated as potential cardioprotective therapeutic, clinical data are limited and does not suggest that the use of these agents promotes the survival of patients undergoing cardiotoxic treatments. The identification of erythropoietin receptor in hematopoietic tissues, including the heart, as well as its marked cardioprotective effect during ischemia have led to the hypothesis that erythropoietin may be able to prevent anthracycline-induced cardiomyopathy. Addressing this hypothesis is the objective of this work. |
| format | Article |
| id | doaj-art-801786fae5814a80bb3f3955fa58b065 |
| institution | Kabale University |
| issn | 1727-897X |
| language | Spanish |
| publishDate | 2010-08-01 |
| publisher | Centro Provincial de Información de Ciencias Médicas. Cienfuegos |
| record_format | Article |
| series | Medisur |
| spelling | doaj-art-801786fae5814a80bb3f3955fa58b0652025-01-30T21:28:42ZspaCentro Provincial de Información de Ciencias Médicas. CienfuegosMedisur1727-897X2010-08-0184280288610Erythropoietin: from erythropoiesis to cardioprotectionLiermis Michael Dita Salabert0Ivis Mendoza Hernández1Rafael Alejandro Gómez Baute2Elena García López3Lázaro E. de la Cruz Avilés4Aramis Núñez Quintana5Hospital General Universitario "Dr. Gustavo Aldereguía Lima" . Cienfuegos.Centro Nacional Coordinador de Ensayos Clínicos. Ciudad de La Habana.Hospital General Universitario "Dr. Gustavo Aldereguía Lima" . Cienfuegos.Centro Nacional Coordinador de Ensayos Clínicos. Ciudad de La Habana.Hospital General Universitario “Dr. Gustavo Aldereguía Lima". Cienfuegos.Hospital “Hermanos Ameijeiras”. Ciudad de La Habana.Many of the drugs that has shown promise in the treatment of hematologic malignancies and solid tumors, associated with a high potential cardiotoxic. Within this group stand anthracyclines, identified as the type of chemotherapy most likely to cause heart damage, short or long term. With the improvement achieved in the survival of patients with these diseases, this adverse event has become a major concern for the scientific community. Although many agents have been evaluated as potential cardioprotective therapeutic, clinical data are limited and does not suggest that the use of these agents promotes the survival of patients undergoing cardiotoxic treatments. The identification of erythropoietin receptor in hematopoietic tissues, including the heart, as well as its marked cardioprotective effect during ischemia have led to the hypothesis that erythropoietin may be able to prevent anthracycline-induced cardiomyopathy. Addressing this hypothesis is the objective of this work.http://medisur.sld.cu/index.php/medisur/article/view/1159receptores de eritropoyetinaeritropoyetinatoxicidad de medicamentosmiocardiopatías cardiotoxinasantraciclinas/efectos adversos |
| spellingShingle | Liermis Michael Dita Salabert Ivis Mendoza Hernández Rafael Alejandro Gómez Baute Elena García López Lázaro E. de la Cruz Avilés Aramis Núñez Quintana Erythropoietin: from erythropoiesis to cardioprotection Medisur receptores de eritropoyetina eritropoyetina toxicidad de medicamentos miocardiopatías cardiotoxinas antraciclinas/efectos adversos |
| title | Erythropoietin: from erythropoiesis to cardioprotection |
| title_full | Erythropoietin: from erythropoiesis to cardioprotection |
| title_fullStr | Erythropoietin: from erythropoiesis to cardioprotection |
| title_full_unstemmed | Erythropoietin: from erythropoiesis to cardioprotection |
| title_short | Erythropoietin: from erythropoiesis to cardioprotection |
| title_sort | erythropoietin from erythropoiesis to cardioprotection |
| topic | receptores de eritropoyetina eritropoyetina toxicidad de medicamentos miocardiopatías cardiotoxinas antraciclinas/efectos adversos |
| url | http://medisur.sld.cu/index.php/medisur/article/view/1159 |
| work_keys_str_mv | AT liermismichaelditasalabert erythropoietinfromerythropoiesistocardioprotection AT ivismendozahernandez erythropoietinfromerythropoiesistocardioprotection AT rafaelalejandrogomezbaute erythropoietinfromerythropoiesistocardioprotection AT elenagarcialopez erythropoietinfromerythropoiesistocardioprotection AT lazaroedelacruzaviles erythropoietinfromerythropoiesistocardioprotection AT aramisnunezquintana erythropoietinfromerythropoiesistocardioprotection |